| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S0950268812001677 |
| P698 | PubMed publication ID | 22906296 |
| P2093 | author name string | R T Ranallo | |
| C K Porter | |||
| M S Riddle | |||
| N Thura | |||
| P2860 | cites work | Meta-analysis in clinical trials | Q27860779 |
| Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome | Q28238388 | ||
| Challenge studies of human volunteers: ethical issues | Q29051434 | ||
| Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 | Q33876803 | ||
| Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): a systematic review. | Q36474608 | ||
| Postinfectious irritable bowel syndrome--a meta-analysis | Q36574982 | ||
| Infection and musculoskeletal conditions: Reactive arthritis | Q36664045 | ||
| Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road | Q36844719 | ||
| Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. | Q36945836 | ||
| Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei | Q36985066 | ||
| Post-infectious irritable bowel syndrome--a review of the literature. | Q37910823 | ||
| Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile | Q39252440 | ||
| Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2 | Q40687041 | ||
| An analysis of the quantitative relationship between oral temperature and severity of illness in experimental shigellosis | Q40727417 | ||
| Studies with a New Generation of Oral Attenuated Shigella Vaccine: Escherichia coli Bearing Surface Antigens of Shigella flexneri | Q40811928 | ||
| Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge | Q44635104 | ||
| Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection | Q44713046 | ||
| Pathogenesis of Shigella dysenteriae 1 (Shiga) Dysentery | Q46613719 | ||
| Inoculum size in shigellosis and implications for expected mode of transmission | Q47172816 | ||
| Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine | Q50201269 | ||
| Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease | Q50464343 | ||
| A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity | Q54158784 | ||
| The ethical challenge of infection-inducing challenge experiments | Q58668889 | ||
| Sociodemographic factors associated with serum anti-Shigella lipopolysaccharide antibodies and shigellosis | Q68009720 | ||
| Immunity in Shigellosis. II. Protection Induced by Oral Live Vaccine or Primary Infection | Q69156182 | ||
| The response of man to virulent Shigella flexneri 2a | Q72377709 | ||
| Experimental human bacillary dysentery; polyvalent dysentery vaccine in its prevention | Q82188947 | ||
| Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge | Q83063190 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 223-232 | |
| P577 | publication date | 2012-08-21 | |
| P1433 | published in | Epidemiology and Infection | Q5382708 |
| P1476 | title | The Shigella human challenge model | |
| P478 | volume | 141 |
| Q47205506 | A clinically parameterized mathematical model of Shigella immunity to inform vaccine design. |
| Q35944776 | An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli |
| Q92822336 | An Oral Inoculation Infant Rabbit Model for Shigella Infection |
| Q93075052 | Clinical endpoints for efficacy studies |
| Q54246807 | Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score |
| Q91801457 | Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies |
| Q91801443 | Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview |
| Q30279261 | Design, recruitment, and microbiological considerations in human challenge studies. |
| Q37458618 | Effect of wild-type Shigella species and attenuated Shigella vaccine candidates on small intestinal barrier function, antigen trafficking, and cytokine release |
| Q99616537 | Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G |
| Q56378326 | Experimental infection of human volunteers |
| Q99616552 | Immune response characterization after controlled infection with lyophilized Shigella sonnei 53G |
| Q91750459 | Prevalence of Shigella species and its drug resistance pattern in Ethiopia: a systematic review and meta-analysis |
| Q37105553 | Progress and pitfalls in Shigella vaccine research |
| Q26860903 | Salmonella, Shigella, and yersinia |
| Q34518265 | Status of vaccine research and development for Shigella |
| Q38535385 | Systems integration of innate and adaptive immunity |
| Q47266530 | Zika Vaccines: Role for Controlled Human Infection |
Search more.